Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling

Bladder cancer is the 10th most commonly diagnosed cancer in the world, accounting for around 573,000 new cases and 213,000 deaths in 2020. The current standard treatment for locally advanced bladder cancer is neoadjuvant cisplatin (NAC)-based chemotherapy followed by cystectomy. The significant pro...

Full description

Bibliographic Details
Main Authors: Jin-Fen Xiao, Andrew W. Caliri, Jason E. Duex, Dan Theodorescu
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
bladder cancer
fibroblast growth factor receptor
mutation
DNA
targeted therapy
kinase inhibitors
Online Access:https://www.mdpi.com/2072-6694/13/19/4891

Similar Items

Similar Items